Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA and…
Interim analysis of ongoing Phase 2 study shows combination of OCA 5-10 mg + bezafibrate 400 mg improved levels of multiple biochemical markers associated with clinical outcomes in PBC…